Literature DB >> 17572929

The prevalence of coronary arterial abnormalities in pulmonary atresia with intact ventricular septum and their influence on surgical results.

A Louise Calder1, Charles R Peebles, Christopher J Occleshaw.   

Abstract

BACKGROUND: The relatively high mortality in patients with pulmonary atresia and intact ventricular septum may be related to the presence of significant coronary arterial anomalies. This retrospective review of cineangiocardiograms was undertaken to further elucidate the types and variety of such coronary arterial abnormalities, and to assess their effect on postoperative survival. MATERIAL AND
RESULTS: Details regarding coronary arterial anatomy and abnormalities were assessed in 116 patients. We noted the site and severity of lesions, and the presence of fistulous communications from the right ventricle to the coronary arteries, assessing the proportion of left ventricular myocardium affected by coronary arterial interruptions or significant stenoses, in other words, the amount dependent on coronary circulation from the right ventricle. We also measured diameters of the tricuspid and mitral valves. Fistulas were found in 87 patients (75%), interruptions of major coronary arteries in 40 patients (34%), lack of connections between the coronary arteries and the aorta in 18 patients (16%), and single origin of a coronary artery, with the right coronary artery arising from the left, in 6 patients (5%). We found increased mortality in 47 patients (40%) who had a right ventricular-dependent coronary arterial circulation. The presence of fistulas in itself was not associated with higher mortality, but the presence of coronary arterial interruptions (p = 0.05), and a higher myocardial score (p = 0.0009), were.
CONCLUSION: We encountered a higher prevalence of both coronary arterial abnormalities and right ventricular-dependent circulation than previously reported. Awareness of the severity of the coronary arterial abnormalities should assist in planning treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17572929     DOI: 10.1017/S1047951107000893

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  7 in total

1.  Regression of a coronary arterial fistula in an infant with pulmonary atresia and an intact ventricular septum.

Authors:  Anca Popoiu; Andreas Eicken; Thomas Genz; Christian Schreiber; John Hess
Journal:  Pediatr Cardiol       Date:  2009-10-27       Impact factor: 1.655

2.  Critical stenosis of a right ventricle to coronary artery fistula seen at dual-source CT in a newborn with pulmonary atresia and intact ventricular septum.

Authors:  Pierre-Emmanuel Séguéla; Lucile Houyel; Philippe Loget; Jean-Dominique Piot; Jean-François Paul
Journal:  Pediatr Radiol       Date:  2011-04-13

3.  Long-term outcomes after intervention for pulmonary atresia with intact ventricular septum.

Authors:  Lydia K Wright; Jessica H Knight; Amanda S Thomas; Matthew E Oster; James D St Louis; Lazaros K Kochilas
Journal:  Heart       Date:  2019-02-02       Impact factor: 5.994

4.  Predictors of Mortality in Children with Pulmonary Atresia with Intact Ventricular Septum.

Authors:  Stephanie Grant; David Faraoni; James DiNardo; Kirsten Odegard
Journal:  Pediatr Cardiol       Date:  2017-09-04       Impact factor: 1.655

5.  Myocardial strain abnormalities in fetuses with pulmonary atresia and intact ventricular septum.

Authors:  J Cohen; E Binka; K Woldu; S Levasseur; J Glickstein; L R Freud; A Chelliah; J S Chiu; A Shah
Journal:  Ultrasound Obstet Gynecol       Date:  2019-03-12       Impact factor: 7.299

Review 6.  Heart transplantation in biventricular congenital heart disease: indications, techniques, and outcomes.

Authors:  Bassem N Mora; Charles B Huddleston
Journal:  Curr Cardiol Rev       Date:  2011-05

7.  17-Year-Old Man with Pulmonary Atresia and Intact Ventricular Septum Submitted to Fontan Operation, and with Persistent Coronary-Cavitary Fistula.

Authors:  Edmar Atik
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.